Lung, Tempus Aries TP-CA-007

A Second Line Biobank Registry Platform Study in Oncology Patients with KRAS mutated CRC, NSCLC & PDAC. Reference arm study to evaluate ctDNA kinetics and dynamics in response to standard of care therapy in patients with relapsed and metastatic KRAS-mutated NSCLC to enable novel biomarker discovery and drug development.

Lung, Ovation-23-001

The objective of this study is to establish a biorepository and database of specimens to enable future research on the role of molecular genomics in the biological mechanisms of cancers, as well as to validate measures of molecular residual disease in these patient populations. 

Lung, MIRATI 849-017 “KRYSTAL 17”

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Breast, Ovation-23-001

The objective of this study is to establish a biorepository and database of specimens to enable future research on the role of molecular genomics in the biological mechanisms of cancers, as well as to validate measures of molecular residual disease in these patient populations.

Patient Newsletter 2024 October

2024 Breast Cancer Awareness Month with Dr. Tracy Alpert

Prostate Cancer Education Forum

Patient Newsletter 2024 September

Patient Newsletter 2024 August

HOA is the First Cancer Care Center in New York State to Offer Bispecific Antibody Therapy in an Outpatient Setting - Eliminating the Need for a Mandatory Hospital Stay

Hematology-Oncology Associates of CNY (HOA) has successfully treated a patient with bispecific antibody therapy for small-cell lung cancer as an outpatient. Reports show that while this therapy has been successfully administered in the outpatient setting in other parts of the United States, this is the first time it has been provided for someone outside of the hospital in New York State.

Pages